Letrozole is a non-steroidal aromatase inhibitor (AI) and the most potent compound in its class, originally developed for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by inhibiting the aromatase enzyme that converts androgens into estrogen, producing a more complete and aggressive suppression of estrogen than Aromasin or Adex at comparable doses. This potency is precisely why it demands the most caution of the three AIs. In the performance space, letrozole is reserved for situations involving severely elevated estrogen confirmed by bloodwork, or as part of an aggressive gynecomastia elimination protocol when paired with raloxifene. It is supplied at 2 mg per ml and should be dosed in fractions of a ml to stay within the very conservative dose range this compound requires. It is not a default on-cycle AI and should never be used without bloodwork confirmation of the need.

• Competitive non-steroidal aromatase inhibition reversibly binding to the aromatase enzyme's active site and blocking the conversion of androgens into estrogens with greater potency than other non-steroidal AIs, producing near-complete estrogen suppression at full doses

• Systemic estrogen reduction driving circulating estradiol levels significantly lower than baseline, which addresses estrogen-driven conditions but simultaneously removes the beneficial roles estrogen plays in bone density, libido, joint health, and muscle hypertrophy

• HPG axis modulation with reduced estrogen altering hypothalamic and pituitary feedback, affecting LH, FSH, and endogenous testosterone dynamics as a downstream consequence of estrogen suppression

• Reversible binding profile as a non-steroidal compound, letrozole's inhibition is competitive rather than permanent, meaning enzyme activity can recover once the compound clears, but at the doses used this distinction has limited practical significance

• Severe estrogen suppression the most powerful estrogen reduction available among AIs, making it the appropriate tool when other AIs have proven insufficient to control extreme aromatization

• Gynecomastia elimination protocol when paired with raloxifene, the combination of receptor blockade at breast tissue and full estrogen suppression represents one of the most aggressive non-surgical approaches to eliminating existing gyno

• Estrogen-driven side effect management addressing the most severe cases of water retention, elevated blood pressure, and estrogenic bloating that arise from highly aromatizing compound stacks

• Breast cancer treatment its primary medical application, significantly reducing estrogen availability to fuel hormone receptor-positive tumor growth in postmenopausal women

Only use when bloodwork confirms severely elevated estrogen that has not responded adequately to a milder AI. At 2 mg per ml, doses of 500 mcg to 1 mg represent 0.25 to 0.5 ml, requiring careful measurement. When running the gyno elimination protocol with raloxifene, expect to endure the symptoms of low estrogen for the duration as a tradeoff for the aggressive suppression required to address existing breast tissue growth.

• Estrogen crash risk the primary and most serious concern, with crashed estrogen producing erectile dysfunction, joint pain, fatigue, low mood, and impaired muscle growth that can be more debilitating than the high estrogen it was used to treat

• Decreased hypertrophy a meaningful performance cost, as estrogen plays a genuine anabolic role and suppressing it aggressively reduces muscle building capacity during use

• Bone density reduction with long-term or frequent use reducing estrogen levels enough to impair bone remodeling, increasing fracture risk over time

• Hot flashes and menopausal symptoms driven by severe estrogen suppression, particularly at higher doses or with extended use

• Fatigue and weakness reported by some users, linked to the broad physiological impact of significantly reduced estrogen across multiple systems

• Joint and muscle pain consistent with estrogen's protective role in connective tissue and joint lubrication, which becomes apparent when levels are suppressed too aggressively

1. Dombernowsky, P., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer. PubMed. https://pubmed.ncbi.nlm.nih.gov/10500138/

Disclaimer: The information provided is intended solely for educational purposes and should not be considered a replacement for professional medical advice. All compounds referenced are not for human consumption.

Letrozole

Sourcing

USA

Amino Tech

$39.99

OPTIMIZE- 15% OFF

View Product